Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Constantine Mitsiades
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Disorders
Chemicals & Drugs
Anatomy
Physiology
Phenomena
Living Beings
Sign-in to see full Profile
Network (preview)
101
Anderson, Kenneth
71
Hideshima, Teru
68
Mitsiades, Nicholas
62
Munshi, Nikhil
53
Chauhan, Dharminder
44
Richardson, Paul
31
Poulaki, Vassiliki
29
podar, klaus
20
Richardson, Paul
20
Schlossman, Robert
19
Tai, Yu-Tzu
18
Catley, Laurence
16
Treon, Steve
13
Raje, Noopur
13
Koutsilieris, Michael
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Constantine Mitsiades (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Negri Joseph M; McMillin Douglas W; Delmore Jake; Mitsiades Nicholas; Hayden Patrick; Klippel Steffen; Hideshima Teru; Chauhan Dharminder; Munshi Nikhil C; Buser Carolyn A; Pollard John; Richardson Paul G; Anderson Kenneth C; Mitsiades Constantine S
In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465.
British journal of haematology 2009;147(5):672-6.
-
2009: Laubach Jacob P; Mitsiades Constantine S; Mahindra Anuj; Schlossman Robert L; Hideshima Teru; Chauhan Dharminder; Carreau Nicole A; Ghobrial Irene M; Raje Noopur; Munshi Nikhil C; Anderson Kenneth C; Richardson Paul G
Novel therapies in the treatment of multiple myeloma.
Journal of the National Comprehensive Cancer Network : JNCCN 2009;7(9):947-60.
-
2009: Blotta Simona; Tassone Pierfrancesco; Prabhala Rao H; Tagliaferri Piersandro; Cervi David; Amin Samir; Jakubikova Jana; Tai Yu-Tzu; Podar Klaus; Mitsiades Constantine S; Zullo Alessandro; Franco Brunella; Anderson Kenneth C; Munshi Nikhil C
Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance.
Blood 2009;114(15):3276-84.
-
2009: Iliaki Eirini; Poulaki Vassiliki; Mitsiades Nicholas; Mitsiades Constantine S; Miller Joan W; Gragoudas Evangelos S
Role of alpha 4 integrin (CD49d) in the pathogenesis of diabetic retinopathy.
Investigative ophthalmology & visual science 2009;50(10):4898-904.
-
2009: Poulaki Vassiliki; Mitsiades Constantine S; Kotoula Vassiliki; Negri Joseph; McMullan Ciaran; Miller Joan W; Marks Paul A; Mitsiades Nicholas
Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.
Investigative ophthalmology & visual science 2009;50(9):4072-9.
-
2009: McMillin Douglas W; Ooi Melissa; Delmore Jake; Negri Joseph; Hayden Patrick; Mitsiades Nicolas; Jakubikova Jana; Maira Sauveur-Michel; Garcia-Echeverria Carlos; Schlossman Robert; Munshi Nikhil C; Richardson Paul G; Anderson Kenneth C; Mitsiades Constantine S
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
Cancer research 2009;69(14):5835-42.
-
2009: Richardson Paul G; Xie Wanling; Mitsiades Constantine; Chanan-Khan Asher A; Lonial Sagar; Hassoun Hani; Avigan David E; Oaklander Anne Louise; Kuter David J; Wen Patrick Y; Kesari Santosh; Briemberg Hannah R; Schlossman Robert L; Munshi Nikhil C; Heffner L Thompson; Doss Deborah; Esseltine Dixie-Lee; Weller Edie; Anderson Kenneth C; Amato Anthony A
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(21):3518-25.
-
2009: Hideshima Teru; Ikeda Hiroshi; Chauhan Dharminder; Okawa Yutaka; Raje Noopur; Podar Klaus; Mitsiades Constantine; Munshi Nikhil C; Richardson Paul G; Carrasco Ruben D; Anderson Kenneth C
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
Blood 2009;114(5):1046-52.
-
2009: Fulciniti Mariateresa; Tassone Pierfrancesco; Hideshima Teru; Vallet Sonia; Nanjappa Puru; Ettenberg Seth A; Shen Zhenxin; Patel Nipun; Tai Yu-Tzu; Chauhan Dharminder; Mitsiades Constantine; Prabhala Rao; Raje Noopur; Anderson Kenneth C; Stover David R; Munshi Nikhil C
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma.
Blood 2009;114(2):371-9.
-
2009: Kotoula Vassiliki; Sozopoulos Elias; Litsiou Helen; Fanourakis Galinos; Koletsa Triantafyllia; Voutsinas Gerassimos; Tseleni-Balafouta Sophia; Mitsiades Constantine S; Wellmann Axel; Mitsiades Nicholas
Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas.
Endocrine-related cancer 2009;16(2):565-72.
-
2009: Laubach Jacob P; Mitsiades Constantine S; Roccaro Aldo M; Ghobrial Irene M; Anderson Kenneth C; Richardson Paul G
Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia.
Leukemia & lymphoma 2009;50(5):694-702.
-
2009: Mitsiades Constantine S; Hideshima Teru; Chauhan Dharminder; McMillin Douglas W; Klippel Steffen; Laubach Jacob P; Munshi Nikhil C; Anderson Kenneth C; Richardson Paul G
Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.
Seminars in hematology 2009;46(2):166-75.
-
2009: Mitsiades Constantine S; Rouleau Cecile; Echart Cinara; Menon Krishna; Teicher Beverly; Distaso Maria; Palumbo Antonio; Boccadoro Mario; Anderson Kenneth C; Iacobelli Massimo; Richardson Paul G
Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(4):1210-21.
-
2008: Mitsiades Constantine S; Ocio Enrique M; Pandiella Atanasio; Maiso Patricia; Gajate Consuelo; Garayoa Mercedes; Vilanova David; Montero Juan Carlos; Mitsiades Nicholas; McMullan Ciaran J; Munshi Nikhil C; Hideshima Teru; Chauhan Dharminder; Aviles Pablo; Otero Gabriel; Faircloth Glynn; Mateos M Victoria; Richardson Paul G; Mollinedo Faustino; San-Miguel Jesus F; Anderson Kenneth C
Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo.
Cancer research 2008;68(13):5216-25.
-
2008: Richardson Paul G; Mitsiades Constantine; Schlossman Robert; Ghobrial Irene; Hideshima Teru; Munshi Nikhil; Anderson Kenneth C
Bortezomib in the front-line treatment of multiple myeloma.
Expert review of anticancer therapy 2008;8(7):1053-72.
-
2008: Munshi Nikhil C; Mitsiades Constantine; Richardson Paul G; Anderson Kenneth C
Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma.
Nature clinical practice. Oncology 2008;5(7):374-5.
-
2008: Shammas M A; Koley H; Bertheau R C; Neri P; Fulciniti M; Tassone P; Blotta S; Protopopov A; Mitsiades C; Batchu R B; Anderson K C; Chin A; Gryaznov S; Munshi N C
Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(7):1410-8.
-
2008: Weisberg Ellen; Wright Renee D; McMillin Douglas W; Mitsiades Constantine; Ray Arghya; Barrett Rosemary; Adamia Sophia; Stone Richard; Galinsky Ilene; Kung Andrew L; Griffin James D
Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells.
Molecular cancer therapeutics 2008;7(5):1121-9.
-
2008: Richardson Paul; Mitsiades Constantine; Colson Kathleen; Reilly Eileen; McBride Laura; Chiao Judy; Sun Linda; Ricker Justin; Rizvi Syed; Oerth Carol; Atkins Barbara; Fearen Ivy; Anderson Kenneth; Siegel David
Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma.
Leukemia & lymphoma 2008;49(3):502-7.
-
2007: Mitsiades Constantine S; Hayden Patrick J; Anderson Kenneth C; Richardson Paul G
From the bench to the bedside: emerging new treatments in multiple myeloma.
Best practice & research. Clinical haematology 2007;20(4):797-816.
-
2007: Kastritis Efstathios; Mitsiades Constantine S; Dimopoulos Meletios A; Richardson Paul G
Management of relapsed and relapsed refractory myeloma.
Hematology/oncology clinics of North America 2007;21(6):1175-215, x.
-
2007: Mitsiades Constantine S; Anderson Kenneth C; Carrasco Daniel R
Mouse models of human myeloma.
Hematology/oncology clinics of North America 2007;21(6):1051-69, viii.
-
2007: Mitsiades Constantine S; McMillin Douglas W; Klippel Steffen; Hideshima Teru; Chauhan Dharminder; Richardson Paul G; Munshi Nikhil C; Anderson Kenneth C
The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies.
Hematology/oncology clinics of North America 2007;21(6):1007-34, vii-viii.
-
2007: Mitsiades Constantine S; Hayden Patrick; Kotoula Vassiliki; McMillin Douglas W; McMullan Ciaran; Negri Joseph; Delmore Jake E; Poulaki Vassiliki; Mitsiades Nicholas
Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition.
The Journal of clinical endocrinology and metabolism 2007;92(12):4845-52.
-
2007: Hayden Patrick J; Mitsiades Constantine S; Anderson Kenneth C; Richardson Paul G
Novel therapies in myeloma.
Current opinion in hematology 2007;14(6):609-15.
-
2007: Poulaki Vassiliki; Mitsiades Constantine S; Kotoula Vassiliki; Negri Joseph; McMillin Douglas; Miller Joan W; Mitsiades Nicholas
The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
Investigative ophthalmology & visual science 2007;48(10):4706-19.
-
2007: Hatjiharissi Evdoxia; Xu Lian; Santos Daniel Ditzel; Hunter Zachary R; Ciccarelli Bryan T; Verselis Sigitas; Modica Michael; Cao Yang; Manning Robert J; Leleu Xavier; Dimmock Elizabeth A; Kortsaris Alexandros; Mitsiades Constantine; Anderson Kenneth C; Fox Edward A; Treon Steven P
Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism.
Blood 2007;110(7):2561-4.
-
2007: Hideshima Teru; Catley Laurence; Raje Noopur; Chauhan Dharminder; Podar Klaus; Mitsiades Constantine; Tai Yu-Tzu; Vallet Sonia; Kiziltepe Tanyel; Ocio Enrique; Ikeda Hiroshi; Okawa Yutaka; Hideshima Hiromasa; Munshi Nikhil C; Yasui Hiroshi; Richardson Paul G; Anderson Kenneth C
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.
British journal of haematology 2007;138(6):783-91.
-
2007: Hideshima Teru; Mitsiades Constantine; Tonon Giovanni; Richardson Paul G; Anderson Kenneth C
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.
Nature reviews. Cancer 2007;7(8):585-98.
-
2007: Weisberg Ellen; Kung Andrew L; Wright Renee D; Moreno Daisy; Catley Laurie; Ray Arghya; Zawel Leigh; Tran Mary; Cools Jan; Gilliland Gary; Mitsiades Constantine; McMillin Douglas W; Jiang Jingrui; Hall-Meyers Elizabeth; Griffin James D
Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells.
Molecular cancer therapeutics 2007;6(7):1951-61.
-
2007: Mitsiades Constantine S; Mitsiades Nicholas S; Richardson Paul G; Munshi Nikhil C; Anderson Kenneth C
Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment.
Journal of cellular biochemistry 2007;101(4):950-68.
-
2007: Munshi Nikhil C; Mitsiades Constantine S; Richardson Paul G; Anderson Kenneth C
Does maintenance therapy with thalidomide benefit patients with multiple myeloma?
Nature clinical practice. Oncology 2007;4(7):394-5.
-
2007: Poulaki Vassiliki; Iliaki Eirini; Mitsiades Nicholas; Mitsiades Constantine S; Paulus Yiannis N; Bula Deisy V; Gragoudas Evangelos S; Miller Joan W
Inhibition of Hsp90 attenuates inflammation in endotoxin-induced uveitis.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2007;21(9):2113-23.
-
2007: Kiziltepe Tanyel; Hideshima Teru; Ishitsuka Kenji; Ocio Enrique M; Raje Noopur; Catley Laurence; Li Chun-Qi; Trudel Laura J; Yasui Hiroshi; Vallet Sonia; Kutok Jeffery L; Chauhan Dharminder; Mitsiades Constantine S; Saavedra Joseph E; Wogan Gerald N; Keefer Larry K; Shami Paul J; Anderson Kenneth C
JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells.
Blood 2007;110(2):709-18.
-
2007: Ghobrial Joanne; Ghobrial Irene M; Mitsiades Constantine; Leleu Xavier; Hatjiharissi Evdoxia; Moreau Anne-Sophie; Roccaro Aldo; Schlossman Robert; Hideshima Teru; Anderson Kenneth C; Richardson Paul
Novel therapeutic avenues in myeloma: changing the treatment paradigm.
Oncology (Williston Park, N.Y.) 2007;21(7):785-92; discussion 798-800.
-
2007: Richardson Paul G; Mitsiades Constantine; Schlossman Robert; Munshi Nikhil; Anderson Kenneth
New drugs for myeloma.
The oncologist 2007;12(6):664-89.
-
2007: Bae Jooeun; Mitsiades Constantine; Tai Yu-Tzu; Bertheau Robert; Shammas Masood; Batchu Ramesh Babu; Li Cheng; Catley Lawrence; Prabhala Rao; Anderson Kenneth C; Munshi Nikhil C
Phenotypic and functional effects of heat shock protein 90 inhibition on dendritic cell.
Journal of immunology (Baltimore, Md. : 1950) 2007;178(12):7730-7.
-
2007: Sukhdeo Kumar; Mani Mala; Zhang Yunyu; Dutta Jui; Yasui Hiroshi; Rooney Melissa D; Carrasco Daniel E; Zheng Mei; He Haiying; Tai Yu-Tzu; Mitsiades Constantine; Anderson Kenneth C; Carrasco Daniel R
Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(18):7516-21.
-
2007: Mulligan George; Mitsiades Constantine; Bryant Barb; Zhan Fenghuang; Chng Wee J; Roels Steven; Koenig Erik; Fergus Andrew; Huang Yongsheng; Richardson Paul; Trepicchio William L; Broyl Annemiek; Sonneveld Pieter; Shaughnessy John D; Bergsagel P Leif; Schenkein David; Esseltine Dixie-Lee; Boral Anthony; Anderson Kenneth C
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.
Blood 2007;109(8):3177-88.
-
2007: Mitsiades Constantine S; Negri Joseph; McMullan Ciaran; McMillin Douglas W; Sozopoulos Elias; Fanourakis Galinos; Voutsinas Gerassimos; Tseleni-Balafouta Sophia; Poulaki Vassiliki; Batt David; Mitsiades Nicholas
Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.
Molecular cancer therapeutics 2007;6(3):1070-8.
-
2007: Ghobrial Irene M; Leleu Xavier; Hatjiharissi Evdoxia; Hideshima Teru; Mitsiades Constantine; Schlossman Robert; Anderson Kenneth C; Richardson Paul
Emerging drugs in multiple myeloma.
Expert opinion on emerging drugs 2007;12(1):155-63.
-
2007: Richardson Paul G; Hideshima Teru; Mitsiades Constantine; Anderson Kenneth C
The emerging role of novel therapies for the treatment of relapsed myeloma.
Journal of the National Comprehensive Cancer Network : JNCCN 2007;5(2):149-62.
-
2007: Chauhan Dharminder; Neri Paola; Velankar Mugdha; Podar Klaus; Hideshima Teru; Fulciniti Mariateresa; Tassone Pierfrancesco; Raje Noopur; Mitsiades Constantine; Mitsiades Nicholas; Richardson Paul; Zawel Leigh; Tran Mary; Munshi Nikhil; Anderson Kenneth C
Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM).
Blood 2007;109(3):1220-7.
-
2007: Aivado Manuel; Spentzos Dimitrios; Germing Ulrich; Alterovitz Gil; Meng Xiao-Ying; Grall Franck; Giagounidis Aristoteles A N; Klement Giannoula; Steidl Ulrich; Otu Hasan H; Czibere Akos; Prall Wolf C; Iking-Konert Christof; Shayne Michelle; Ramoni Marco F; Gattermann Norbert; Haas Rainer; Mitsiades Constantine S; Fung Eric T; Libermann Towia A
Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(4):1307-12.
-
2007: Richardson Paul; Mitsiades Constantine; Schlossman Robert; Ghobrial Irene; Hideshima Teru; Chauhan Dharminder; Munshi Nikhil; Anderson Kenneth
The treatment of relapsed and refractory multiple myeloma.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2007;():317-23.
-
2006: Richardson Paul G; Mitsiades Constantine S; Munshi Nikhil C; Anderson Kenneth C
Can thalidomide improve outcome in patients with multiple myeloma?
Nature clinical practice. Oncology 2006;3(11):590-1.
-
2006: Richardson Paul G; Mitsiades Constantine; Ghobrial Irene; Anderson Kenneth
Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma.
Current opinion in oncology 2006;18(6):598-608.
-
2006: Richardson Paul G; Blood Emily; Mitsiades Constantine S; Jagannath Sundar; Zeldenrust Steven R; Alsina Melissa; Schlossman Robert L; Rajkumar S Vincent; Desikan K Raman; Hideshima Teru; Munshi Nikhil C; Kelly-Colson Kathleen; Doss Deborah; McKenney Mary L; Gorelik Svetlana; Warren Diane; Freeman Andrea; Rich Rebecca; Wu Anfang; Olesnyckyj Marta; Wride Kenton; Dalton William S; Zeldis Jerome; Knight Robert; Weller Edie; Anderson Kenneth C
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Blood 2006;108(10):3458-64.
-
2006: Mitsiades Constantine S; Mitsiades Nicholas; Hideshima Teru; Richardson Paul G; Anderson Kenneth C
Proteasome inhibition as a new therapeutic principle in hematological malignancies.
Current drug targets 2006;7(10):1341-7.
-
2006: Hideshima Teru; Neri Paola; Tassone Pierfranchesco; Yasui Hiroshi; Ishitsuka Kenji; Raje Noopur; Chauhan Dharminder; Podar Klaus; Mitsiades Constantine; Dang Lenny; Munshi Nikhil; Richardson Paul; Schenkein David; Anderson Kenneth C
MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(19):5887-94.
-
2006: Mitsiades Constantine S; McMillin Douglas; Kotoula Vassiliki; Poulaki Vassiliki; McMullan Ciaran; Negri Joseph; Fanourakis Galinos; Tseleni-Balafouta Sophia; Ain Kenneth B; Mitsiades Nicholas
Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
The Journal of clinical endocrinology and metabolism 2006;91(10):4013-21.
-
2006: Mitsiades Constantine S; Bogdanos John; Karamanolakis Dimitrios; Milathianakis Constantine; Dimopoulos Theodoros; Koutsilieris Michael
Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer.
Anticancer research 2006;26(5B):3693-700.
-
2006: Mitsiades Constantine S; Kotoula Vassiliki; Poulaki Vassiliki; Sozopoulos Elias; Negri Joseph; Charalambous Elpida; Fanourakis Galinos; Voutsinas Gerassimos; Tseleni-Balafouta Sophia; Mitsiades Nicholas
Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis.
The Journal of clinical endocrinology and metabolism 2006;91(9):3662-6.
-
2006: Richardson Paul G; Mitsiades Constantine; Hideshima Teru; Anderson Kenneth C
Lenalidomide in multiple myeloma.
Expert review of anticancer therapy 2006;6(8):1165-73.
-
2006: Shringarpure Reshma; Catley Laurence; Bhole Deepak; Burger Renate; Podar Klaus; Tai Yu-Tzu; Kessler Benedikt; Galardy Paul; Ploegh Hidde; Tassone Pierfrancesco; Hideshima Teru; Mitsiades Constantine; Munshi Nikhil C; Chauhan Dharminder; Anderson Kenneth C
Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.
British journal of haematology 2006;134(2):145-56.
-
2006: Mitsiades Constantine S; Mitsiades Nicholas S; Munshi Nikhil C; Richardson Paul G; Anderson Kenneth C
The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions.
European journal of cancer (Oxford, England : 1990) 2006;42(11):1564-73.
-
2006: Mitsiades Constantine S; Poulaki Vassiliki; Fanourakis Galinos; Sozopoulos Elias; McMillin Douglas; Wen Zhaoqin; Voutsinas Gerassimos; Tseleni-Balafouta Sophia; Mitsiades Nicholas
Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(12):3705-12.
-
2006: Hideshima Teru; Catley Laurence; Yasui Hiroshi; Ishitsuka Kenji; Raje Noopur; Mitsiades Constantine; Podar Klaus; Munshi Nikhil C; Chauhan Dharminder; Richardson Paul G; Anderson Kenneth C
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.
Blood 2006;107(10):4053-62.
-
2006: Mitsiades Constantine S; Mitsiades Nicholas S; McMullan Ciaran J; Poulaki Vassiliki; Kung Andrew L; Davies Faith E; Morgan Gareth; Akiyama Masaharu; Shringarpure Reshma; Munshi Nikhil C; Richardson Paul G; Hideshima Teru; Chauhan Dharminder; Gu Xuesong; Bailey Charles; Joseph Marie; Libermann Towia A; Rosen Neal S; Anderson Kenneth C
Antimyeloma activity of heat shock protein-90 inhibition.
Blood 2006;107(3):1092-100.
-
2006: Richardson Paul G; Mitsiades Constantine; Hideshima Teru; Anderson Kenneth C
Bortezomib: proteasome inhibition as an effective anticancer therapy.
Annual review of medicine 2006;57():33-47.
-
2005: Chen Jing; Lee Benjamin H; Williams Ifor R; Kutok Jeffery L; Mitsiades Constantine S; Duclos Nicole; Cohen Sarah; Adelsperger Jennifer; Okabe Rachel; Coburn Allison; Moore Sandra; Huntly Brian J P; Fabbro Doriano; Anderson Kenneth C; Griffin James D; Gilliland Dwight Gary
FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies.
Oncogene 2005;24(56):8259-67.
-
2005: Chauhan Dharminder; Catley Laurence; Li Guilan; Podar Klaus; Hideshima Teru; Velankar Mugdha; Mitsiades Constantine; Mitsiades Nicolas; Yasui Hiroshi; Letai Anthony; Ovaa Huib; Berkers Celia; Nicholson Benjamin; Chao Ta-Hsiang; Neuteboom Saskia T C; Richardson Paul; Palladino Michael A; Anderson Kenneth C
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.
Cancer cell 2005;8(5):407-19.
-
2005: Richardson Paul G; Schlossman Robert; Mitsiades Constantine; Hideshima Teru; Munshi Nikhil; Anderson Kenneth
Emerging trends in the clinical use of bortezomib in multiple myeloma.
Clinical lymphoma & myeloma 2005;6(2):84-8.
-
2005: Yasui Hiroshi; Hideshima Teru; Raje Noopur; Roccaro Aldo M; Shiraishi Norihiko; Kumar Shaji; Hamasaki Makoto; Ishitsuka Kenji; Tai Yu-Tzu; Podar Klaus; Catley Laurence; Mitsiades Constantine S; Richardson Paul G; Albert Rainer; Brinkmann Volker; Chauhan Dharminder; Anderson Kenneth C
FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
Cancer research 2005;65(16):7478-84.
-
2005: Mitsiades Constantine S; Mitsiades Nicholas
Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling.
Expert review of anticancer therapy 2005;5(3):487-99.
-
2005: Mitsiades Constantine S; Mitsiades Nicholas; Hideshima Teru; Richardson Paul G; Anderson Kenneth C
Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
Expert review of anticancer therapy 2005;5(3):465-76.
-
2005: Mitsiades Constantine S; Poulaki Vassiliki; McMullan Ciaran; Negri Joseph; Fanourakis Galinos; Goudopoulou Athina; Richon Victoria M; Marks Paul A; Mitsiades Nicholas
Novel histone deacetylase inhibitors in the treatment of thyroid cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(10):3958-65.
-
2005: Richardson Paul G; Mitsiades Constantine
Bortezomib: proteasome inhibition as an effective anticancer therapy.
Future oncology (London, England) 2005;1(2):161-71.
-
2005: Chauhan Dharminder; Hideshima Teru; Mitsiades Constantine; Richardson Paul; Anderson Kenneth C
Proteasome inhibitor therapy in multiple myeloma.
Molecular cancer therapeutics 2005;4(4):686-92.
-
2005: Mitsiades Constantine S
CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q.
Haematologica 2005;90(4):436-7.
-
2005: Hideshima Teru; Chauhan Dharminder; Ishitsuka Kenji; Yasui Hiroshi; Raje Noopur; Kumar Shaji; Podar Klaus; Mitsiades Constantine; Hideshima Hiromasa; Bonham Lynn; Munshi Nikhil C; Richardson Paul G; Singer Jack W; Anderson Kenneth C
Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.
Oncogene 2005;24(19):3121-9.
-
2005: Mitsiades Constantine S; Mitsiades Nicholas
Thyroid carcinoma cells and Fas-mediated apoptosis.
Thyroid : official journal of the American Thyroid Association 2005;15(2):178-9.
-
2005: Richardson Paul G; Mitsiades Constantine; Hideshima Teru; Anderson Kenneth C
Proteasome inhibition in the treatment of cancer.
Cell cycle (Georgetown, Tex.) 2005;4(2):290-6.
-
2005: Poulaki Vassiliki; Mitsiades Constantine S; McMullan Ciaran; Fanourakis Galinos; Negri Joseph; Goudopoulou Athina; Halikias Ioannis X; Voutsinas Gerassimos; Tseleni-Balafouta Sophia; Miller Joan W; Mitsiades Nicholas
Human retinoblastoma cells are resistant to apoptosis induced by death receptors: role of caspase-8 gene silencing.
Investigative ophthalmology & visual science 2005;46(1):358-66.
-
2005: Lin Boris; Catley Laurence; LeBlanc Richard; Mitsiades Constantine; Burger Renate; Tai Yu-Tzu; Podar Klaus; Wartmann Markus; Chauhan Dharminder; Griffin James D; Anderson Kenneth C
Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo.
Blood 2005;105(1):350-7.
-
2005: Mitsiades Constantine S; Mitsiades Nicholas; Hideshima Teru; Richardson Paul G; Anderson Kenneth C
Proteasome inhibitors as therapeutics.
Essays in biochemistry 2005;41():205-18.
-
2005: Richardson Paul G; Mitsiades Constantine S; Hideshima Teru; Anderson Kenneth C
Novel biological therapies for the treatment of multiple myeloma.
Best practice & research. Clinical haematology 2005;18(4):619-34.
-
2004: Raje Noopur; Kumar Shaji; Hideshima Teru; Ishitsuka Kenji; Chauhan Dharminder; Mitsiades Constantine; Podar Klaus; Le Gouill Steven; Richardson Paul; Munshi Nikhil C; Stirling David I; Antin Joseph H; Anderson Kenneth C
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma.
Blood 2004;104(13):4188-93.
-
2004: Mitsiades Constantine S
Molecular profiles of proteasome inhibition in plasma cell dyscrasias.
Journal of the National Comprehensive Cancer Network : JNCCN 2004;2 Suppl 4():S23-7.
-
2004: Mitsiades Constantine S; Mitsiades Nicholas; Munshi Nikhil C; Anderson Kenneth C
Focus on multiple myeloma.
Cancer cell 2004;6(5):439-44.
-
2004: Hideshima Teru; Podar Klaus; Chauhan Dharminder; Ishitsuka Kenji; Mitsiades Constantine; Tai Yu-Tzu; Hamasaki Makoto; Raje Noopur; Hideshima Hiromasa; Schreiner George; Nguyen Aaron N; Navas Tony; Munshi Nikhil C; Richardson Paul G; Higgins Linda S; Anderson Kenneth C
p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.
Oncogene 2004;23(54):8766-76.
-
2004: Chauhan Dharminder; Li Guilan; Podar Klaus; Hideshima Teru; Mitsiades Constantine; Schlossman Robert; Munshi Nikhil; Richardson Paul; Cotter Finbarr E; Anderson Kenneth C
Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.
Blood 2004;104(8):2458-66.
-
2004: Poulaki Vassiliki; Joussen Antonia M; Mitsiades Nicholas; Mitsiades Constantine S; Iliaki Eirini F; Adamis Anthony P
Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy.
The American journal of pathology 2004;165(2):457-69.
-
2004: Richardson Paul; Schlossman Robert; Jagannath Sundar; Alsina Melissa; Desikan Raman; Blood Emily; Weller Edie; Mitsiades Constantine; Hideshima Teru; Davies Faith; Doss Deborah; Freeman Andrea; Bosch Joan; Patin John; Knight Robert; Zeldis Jerome; Dalton William; Anderson Kenneth
Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity.
Mayo Clinic proceedings. Mayo Clinic 2004;79(7):875-82.
-
2004: Koutsilieris Michael; Mitsiades Constantine S; Bogdanos John; Dimopoulos Theodoros; Karamanolakis Dimitrios; Milathianakis Constantine; Tsintavis Athanassios
Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(13):4398-405.
-
2004: Mitsiades Constantine S; Mitsiades Nicholas
CC-5013 (Celgene).
Current opinion in investigational drugs (London, England : 2000) 2004;5(6):635-47.
-
2004: Mitsiades Constantine S; Mitsiades Nicholas; Koutsilieris Michael
The Akt pathway: molecular targets for anti-cancer drug development.
Current cancer drug targets 2004;4(3):235-56.
-
2004: Chauhan Dharminder; Li Guilan; Hideshima Teru; Podar Klaus; Shringarpure Reshma; Mitsiades Constantine; Munshi Nikhil; Yew P Renee; Anderson Kenneth C
Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341.
Oncogene 2004;23(20):3597-602.
-
2004: Tai Yu-Tzu; Catley Laurence P; Mitsiades Constantine S; Burger Renate; Podar Klaus; Shringpaure Reshma; Hideshima Teru; Chauhan Dharminder; Hamasaki Makoto; Ishitsuka Kenji; Richardson Paul; Treon Steven P; Munshi Nikhil C; Anderson Kenneth C
Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications.
Cancer research 2004;64(8):2846-52.
-
2004: Chauhan Dharminder; Li Guilan; Podar Klaus; Hideshima Teru; Shringarpure Reshma; Catley Laurence; Mitsiades Constantine; Munshi Nikhil; Tai Yu Tzu; Suh Nanjoo; Gribble Gordon W; Honda Tadashi; Schlossman Robert; Richardson Paul; Sporn Michael B; Anderson Kenneth C
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.
Blood 2004;103(8):3158-66.
-
2004: Karamanakos Peter; Mitsiades Constantine S; Lembessis Peter; Kontos Michael; Trafalis Demetrios; Koutsilieris Michael
Male breast adenocarcinoma in a prostate cancer patient following prolonged anti-androgen monotherapy.
Anticancer research 2004;24(2C):1077-81.
-
2004: Mitsiades Constantine S; Mitsiades Nicholas S; McMullan Ciaran J; Poulaki Vassiliki; Shringarpure Reshma; Akiyama Masaharu; Hideshima Teru; Chauhan Dharminder; Joseph Marie; Libermann Towia A; García-Echeverría Carlos; Pearson Mark A; Hofmann Francesco; Anderson Kenneth C; Kung Andrew L
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.
Cancer cell 2004;5(3):221-30.
-
2004: Chauhan D; Li G; Auclair D; Hideshima T; Podar K; Mitsiades N; Mitsiades C; Chen L B; Munshi N; Saxena S; Anderson K C
2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27.
Apoptosis : an international journal on programmed cell death 2004;9(2):149-55.
-
2004: LeBlanc Richard; Hideshima Teru; Catley Laurence P; Shringarpure Reshma; Burger Renate; Mitsiades Nicholas; Mitsiades Constantine; Cheema Puneet; Chauhan Dharminder; Richardson Paul G; Anderson Kenneth C; Munshi Nikhil C
Immunomodulatory drug costimulates T cells via the B7-CD28 pathway.
Blood 2004;103(5):1787-90.
-
2004: Munshi Nikhil C; Hideshima Teru; Carrasco Daniel; Shammas Masood; Auclair Daniel; Davies Faith; Mitsiades Nicholas; Mitsiades Constantine; Kim Ryung Suk; Li Cheng; Rajkumar S Vincent; Fonseca Rafael; Bergsagel Lief; Chauhan Dharminder; Anderson Kenneth C
Identification of genes modulated in multiple myeloma using genetically identical twin samples.
Blood 2004;103(5):1799-806.
-
2004: Mitsiades Constantine S; Mitsiades Nicholas S; McMullan Ciaran J; Poulaki Vassiliki; Shringarpure Reshma; Hideshima Teru; Akiyama Masaharu; Chauhan Dharminder; Munshi Nikhil; Gu Xuesong; Bailey Charles; Joseph Marie; Libermann Towia A; Richon Victoria M; Marks Paul A; Anderson Kenneth C
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(2):540-5.
-
2004: Mitsiades Constantine S; Lembessis Peter; Sourla Antigone; Milathianakis Constantine; Tsintavis Athanassios; Koutsilieris Michael
Molecular staging by RT-pCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer.
Clinical & experimental metastasis 2004;21(6):495-505.
-
2004: Richardson Paul G; Hideshima Teru; Mitsiades Constantine; Anderson Kenneth
Proteasome inhibition in hematologic malignancies.
Annals of medicine 2004;36(4):304-14.
-
2003: Hideshima Teru; Chauhan Dharminder; Hayashi Toshiaki; Podar Klaus; Akiyama Masaharu; Mitsiades Constantine; MItsiades Nicholas; Gong Baoqing; Bonham Lynn; de Vries Peter; Munshi Nikhil; Richardson Paul G; Singer Jack W; Anderson Kenneth C
Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.
Cancer research 2003;63(23):8428-36.
-
2003: Davies Faith E; Dring Ann M; Li Cheng; Rawstron Andrew C; Shammas Masood A; O'Connor Sheila M; Fenton James A L; Hideshima Teru; Chauhan Dharminder; Tai Isabella T; Robinson Elizabeth; Auclair Daniel; Rees Karen; Gonzalez David; Ashcroft A John; Dasgupta Ranjit; Mitsiades Constantine; Mitsiades Nicholas; Chen Lan B; Wong Wing H; Munshi Nikhil C; Morgan Gareth J; Anderson Kenneth C
Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis.
Blood 2003;102(13):4504-11.
-
2003: Hideshima Teru; Chauhan Dharminder; Hayashi Toshiaki; Akiyama Masaharu; Mitsiades Nicholas; Mitsiades Constantine; Podar Klaus; Munshi Nikhil C; Richardson Paul G; Anderson Kenneth C
Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma.
Oncogene 2003;22(52):8386-93.
-
2003: Poulaki Vassiliki; Mitsiades Constantine S; McMullan Ciaran; Sykoutri Despoina; Fanourakis Galinos; Kotoula Vassiliki; Tseleni-Balafouta Sophia; Koutras Demetrios A; Mitsiades Nicholas
Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas.
The Journal of clinical endocrinology and metabolism 2003;88(11):5392-8.
-
2003: Chauhan Dharminder; Li Guilan; Hideshima Teru; Podar Klaus; Mitsiades Constantine; Mitsiades Nicholas; Catley Laurence; Tai Yu Tzu; Hayashi Toshiaki; Shringarpure Reshma; Burger Renate; Munshi Nikhil; Ohtake Yasuyuki; Saxena Satya; Anderson Kenneth C
Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance.
Blood 2003;102(9):3379-86.
-
2003: Mitsiades Constantine S; Mitsiades Nicholas S; Bronson Ron T; Chauhan Dharminder; Munshi Nikhil; Treon Steven P; Maxwell Christopher A; Pilarski Linda; Hideshima Teru; Hoffman Robert M; Anderson Kenneth C
Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications.
Cancer research 2003;63(20):6689-96.
-
2003: Mitsiades Constantine S; Sykoutri Despoina; McMullan Ciaran; Poulaki Vassiliki; Mitsiades Nicholas
Effect of imatinib mesylate (Gleevec) on anaplastic thyroid carcinoma cell lines.
The Journal of clinical endocrinology and metabolism 2003;88(10):5043-4; author reply 5044.
-
2003: Tai Yu-Tzu; Podar Klaus; Catley Laurence; Tseng Yu-Hua; Akiyama Masaharu; Shringarpure Reshma; Burger Renate; Hideshima Teru; Chauhan Dharminder; Mitsiades Nicholas; Richardson Paul; Munshi Nikhil C; Kahn C Ronald; Mitsiades Constantine; Anderson Kenneth C
Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling.
Cancer research 2003;63(18):5850-8.
-
2003: Chauhan Dharminder; Li Guilan; Sattler Martin; Podar Klaus; Mitsiades Constantine; Mitsiades Nicholas; Munshi Nikhil; Hideshima Teru; Anderson Kenneth C
Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells.
Oncogene 2003;22(40):6296-300.
-
2003: Mitsiades C S; Poulaki V; Mitsiades N
The role of apoptosis-inducing receptors of the tumor necrosis factor family in thyroid cancer.
The Journal of endocrinology 2003;178(2):205-16.
-
2003: Bogdanos J; Karamanolakis D; Tenta R; Tsintavis A; Milathianakis C; Mitsiades C; Koutsilieris M
Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton.
Endocrine-related cancer 2003;10(2):279-89.
-
2003: Chauhan Dharminder; Li Guilan; Hideshima Teru; Podar Klaus; Mitsiades Constantine; Mitsiades Nicholas; Munshi Nikhil; Kharbanda Surender; Anderson Kenneth C
JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells.
The Journal of biological chemistry 2003;278(20):17593-6.
-
2003: Mitsiades Nicholas; Mitsiades Constantine S; Richardson Paul G; McMullan Ciaran; Poulaki Vassiliki; Fanourakis Galinos; Schlossman Robert; Chauhan Dharminder; Munshi Nikhil C; Hideshima Teru; Richon Victoria M; Marks Paul A; Anderson Kenneth C
Molecular sequelae of histone deacetylase inhibition in human malignant B cells.
Blood 2003;101(10):4055-62.
-
2003: Chauhan Dharminder; Li Guilan; Auclair Daniel; Hideshima Teru; Richardson Paul; Podar Klaus; Mitsiades Nicholas; Mitsiades Constantine; Li Cheng; Kim Ryung Suk; Munshi Nikhil; Chen Lan Bo; Wong Wing; Anderson Kenneth C
Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays.
Blood 2003;101(9):3606-14.
-
2003: Mitsiades Constantine S; Mitsiades Nicholas
P2X7 polymorphism and chronic lymphocytic leukaemia.
Lancet 2003;361(9367):1478; author reply 1478-9.
-
2003: Mitsiades Constantine S; Mitsiades Nicholas; Richardson Paul G; Treon Steven P; Anderson Kenneth C
Novel biologically based therapies for Waldenstrom's macroglobulinemia.
Seminars in oncology 2003;30(2):309-12.
-
2003: Treon Steven P; Kelliher Abigail; Keele Beverly; Frankel Stanley; Emmanouilides Christos; Kimby Eva; Schlossman Robert; Mitsiades Nicholas; Mitsiades Constantine; Preffer Frederic; Anderson Kenneth C
Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations.
Seminars in oncology 2003;30(2):248-52.
-
2003: Mitsiades Constantine S; Mitsiades Nicholas; Treon Steven P; Anderson Kenneth C
Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasias.
Seminars in oncology 2003;30(2):156-60.
-
2003: Tai Yu-Tzu; Podar Klaus; Mitsiades Nicholas; Lin Boris; Mitsiades Constantine; Gupta Deepak; Akiyama Masaharu; Catley Laurence; Hideshima Teru; Munshi Nikhil C; Treon Steven P; Anderson Kenneth C
CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling.
Blood 2003;101(7):2762-9.
-
2003: Mitsiades Nicholas; Mitsiades Constantine S; Richardson Paul G; Poulaki Vassiliki; Tai Yu-Tzu; Chauhan Dharminder; Fanourakis Galinos; Gu Xuesong; Bailey Charles; Joseph Marie; Libermann Towia A; Schlossman Robert; Munshi Nikhil C; Hideshima Teru; Anderson Kenneth C
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.
Blood 2003;101(6):2377-80.
-
2003: Hideshima Teru; Mitsiades Constantine; Akiyama Masaharu; Hayashi Toshiaki; Chauhan Dharminder; Richardson Paul; Schlossman Robert; Podar Klaus; Munshi Nikhil C; Mitsiades Nicholas; Anderson Kenneth C
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.
Blood 2003;101(4):1530-4.
-
2003: Akiyama Masaharu; Hideshima Teru; Hayashi Toshiaki; Tai Yu-Tzu; Mitsiades Constantine S; Mitsiades Nicholas; Chauhan Dharminder; Richardson Paul; Munshi Nikhil C; Anderson Kenneth C
Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein.
Cancer research 2003;63(1):18-21.
-
2003: Joussen Antonia M; Poulaki Vassiliki; Mitsiades Nicholas; Cai Wen-yi; Suzuma Izumi; Pak John; Ju Shyr-Te; Rook Susan L; Esser Peter; Mitsiades Constantin S; Kirchhof Bernd; Adamis Anthony P; Aiello Lloyd Paul
Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2003;17(1):76-8.
-
2002: Poulaki Vassiliki; Mitsiades Constantine S; Joussen Antonia M; Lappas Alexandra; Kirchhof Bernd; Mitsiades Nicholas
Constitutive nuclear factor-kappaB activity is crucial for human retinoblastoma cell viability.
The American journal of pathology 2002;161(6):2229-40.
-
2002: Richardson Paul G; Schlossman Robert L; Weller Edie; Hideshima Teru; Mitsiades Constantine; Davies Faith; LeBlanc Richard; Catley Laurence P; Doss Deborah; Kelly Kathleen; McKenney Mary; Mechlowicz Julie; Freeman Andrea; Deocampo Reggie; Rich Rebecca; Ryoo Joan J; Chauhan Dharminder; Balinski Kathe; Zeldis Jerome; Anderson Kenneth C
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Blood 2002;100(9):3063-7.
-
2002: Mitsiades Nicholas; Mitsiades Constantine S; Poulaki Vassiliki; Chauhan Dharminder; Fanourakis Galinos; Gu Xuesong; Bailey Charles; Joseph Marie; Libermann Towia A; Treon Steven P; Munshi Nikhil C; Richardson Paul G; Hideshima Teru; Anderson Kenneth C
Molecular sequelae of proteasome inhibition in human multiple myeloma cells.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(22):14374-9.
-
2002: LeBlanc Richard; Catley Laurence P; Hideshima Teru; Lentzsch Suzanne; Mitsiades Constantine S; Mitsiades Nicholas; Neuberg Donna; Goloubeva Olga; Pien Christine S; Adams Julian; Gupta Deepak; Richardson Paul G; Munshi Nikhil C; Anderson Kenneth C
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.
Cancer research 2002;62(17):4996-5000.
-
2002: Mitsiades Constantine S; Mitsiades Nicholas; Poulaki Vassiliki; Schlossman Robert; Akiyama Masaharu; Chauhan Dharminder; Hideshima Teru; Treon Steven P; Munshi Nikhil C; Richardson Paul G; Anderson Kenneth C
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
Oncogene 2002;21(37):5673-83.
-
2002: Poulaki Vassiliki; Mitsiades Constantine S; Kotoula Vassiliki; Tseleni-Balafouta Sophia; Ashkenazi Avi; Koutras Demetrios A; Mitsiades Nicholas
Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells.
The American journal of pathology 2002;161(2):643-54.
-
2002: Gupta Deepak; Podar Klaus; Tai Yu Tzu; Lin Boris; Hideshima Teru; Akiyama Masaharu; LeBlanc Richard; Catley Laurence; Mitsiades Nicholas; Mitsiades Constantine; Chauhan Dharminder; Munshi Nikhil C; Anderson Kenneth C
beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells.
Experimental hematology 2002;30(7):711-20.
-
2002: Akiyama Masaharu; Hideshima Teru; Hayashi Toshiaki; Tai Yu-Tzu; Mitsiades Constantine S; Mitsiades Nicholas; Chauhan Dharminder; Richardson Paul; Munshi Nikhil C; Anderson Kenneth C
Cytokines modulate telomerase activity in a human multiple myeloma cell line.
Cancer research 2002;62(13):3876-82.
-
2002: Mitsiades Nicholas; Mitsiades Constantine S; Poulaki Vassiliki; Chauhan Dharminder; Richardson Paul G; Hideshima Teru; Munshi Nikhil C; Treon Steven P; Anderson Kenneth C
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.
Blood 2002;99(12):4525-30.
-
2002: Mitsiades Nicholas; Mitsiades Constantine S; Poulaki Vassiliki; Chauhan Dharminder; Richardson Paul G; Hideshima Teru; Munshi Nikhil; Treon Steven P; Anderson Kenneth C
Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications.
Blood 2002;99(11):4079-86.
-
2002: Hideshima Teru; Chauhan Dharminder; Richardson Paul; Mitsiades Constantine; Mitsiades Nicholas; Hayashi Toshiaki; Munshi Nikhil; Dang Lenny; Castro Alfredo; Palombella Vito; Adams Julian; Anderson Kenneth C
NF-kappa B as a therapeutic target in multiple myeloma.
The Journal of biological chemistry 2002;277(19):16639-47.
-
2002: Mitsiades Nicholas; Mitsiades Constantine S; Poulaki Vassiliki; Anderson Kenneth C; Treon Steven P
Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells.
Blood 2002;99(6):2162-71.
-
2002: Koutsilieris Michael; Mitsiades Constantine; Dimopoulos Theodoros; Vacalicos John; Lambou Theocharis; Tsintavis Athanassios; Milathianakis Constantine; Bogdanos John; Karamanolakis Dimitrios
Combination of dexamethasone and a somatostatin analogue in the treatment of advanced prostate cancer.
Expert opinion on investigational drugs 2002;11(2):283-93.
-
2002: Treon Steven P; Pilarski Linda M; Belch Andrew R; Kelliher Abigail; Preffer Frederic I; Shima Yoshihito; Mitsiades Constantine S; Mitsiades Nicholas S; Szczepek Agnieszka J; Ellman Leonard; Harmon David; Grossbard Michael L; Anderson Kenneth C
CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2002;25(1):72-81.
-
2001: Koutsilieris M; Mitsiades C; Dimopoulos T; Ioannidis A; Ntounis A; Lambou T
A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients.
The Journal of clinical endocrinology and metabolism 2001;86(12):5729-36.
-
2001: Mitsiades N; Poulaki V; Mitsiades C S; Koutras D A; Chrousos G P
Apoptosis induced by FasL and TRAIL/Apo2L in the pathogenesis of thyroid diseases.
Trends in endocrinology and metabolism: TEM 2001;12(9):384-90.
-
2001: Sourla A; Lembessis P; Mitsiades C; Dimopoulos T; Skouteris M; Metsinis M; Ntounis A; Ioannidis A; Katsoulis A; Kyragiannis V; Lambou T; Tsintavis A; Koutsilieris M
Conversion of nested reverse-transcriptase polymerase chain reaction from positive to negative status at peripheral blood during androgen ablation therapy is associated with long progression-free survival in stage D2 prostate cancer patients.
Anticancer research 2001;21(5):3565-70.
-
2001: Mitsiades N; Mitsiades C S; Poulaki V; Anderson K C; Treon S P
Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias.
Expert opinion on investigational drugs 2001;10(8):1521-30.
-
2001: Mitsiades C S; Treon S P; Mitsiades N; Shima Y; Richardson P; Schlossman R; Hideshima T; Anderson K C
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.
Blood 2001;98(3):795-804.
-
2001: Podar K; Tai Y T; Davies F E; Lentzsch S; Sattler M; Hideshima T; Lin B K; Gupta D; Shima Y; Chauhan D; Mitsiades C; Raje N; Richardson P; Anderson K C
Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration.
Blood 2001;98(2):428-35.
-
2001: Mitsiades C S; Koutsilieris M
Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer.
Expert opinion on investigational drugs 2001;10(6):1099-115.
-
2001: Mitsiades N; Poulaki V; Mitsiades C S; Anderson K C
Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug.
Expert opinion on investigational drugs 2001;10(6):1075-84.
-
2001: Treon S P; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson K C
Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2001;24(3):263-71.
-
2000: Mitsiades C; Sourla A; Doillon C; Lembessis P; Koutsilieris M
Three-dimensional type I collagen co-culture systems for the study of cell-cell interactions and treatment response in bone metastases.
Journal of musculoskeletal & neuronal interactions 2000;1(2):153-5.
-
2000: Koutsilieris M; Mitsiades C; Lembessis P; Sourla A
Cancer and bone repair mechanism: clinical applications for hormone refractory prostate cancer.
Journal of musculoskeletal & neuronal interactions 2000;1(1):15-7.
-
2000: Koutsilieris M; Mitsiades C; Sourla A
Insulin-like growth factor I and urokinase-type plasminogen activator bioregulation system as a survival mechanism of prostate cancer cells in osteoblastic metastases: development of anti-survival factor therapy for hormone-refractory prostate cancer.
Molecular medicine (Cambridge, Mass.) 2000;6(4):251-67.
Sign-in to see more
